KDR and hepatocellular carcinoma: In 2019, the vascular endothelial growth factor receptor 2 (VEGFR2)-antagonist ramucirumab also received FDA approval as a single agent for HCC [17], while, in 2020, the FDA approved another two combinational mAb therapeutic regimens: nivolumab/ipilimumab and atezolizumab/bevacizumab [18,19].